Macquarie Group’s Protagonist Therapeutics PTGX Stock Holding History

Macquarie Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-283	Closed	-$13.7K	–	1748
2025 Q1	$13.7K	Buy	+283	New	+$11.9K	﹤0.01%	1625
2022 Q3	–	Sell	-307	Closed	-$2.9K	–	2489
2022 Q2	$2K	Hold	307	–	–	﹤0.01%	2558
2022 Q1	$7	Hold	307	–	–	﹤0.01%	2557
2021 Q4	$10K	Hold	307	–	–	﹤0.01%	2514
2021 Q3	$5K	Hold	307	–	–	﹤0.01%	2600
2021 Q2	$14K	Sell	307 -1,432	-82%	-$47.3K	﹤0.01%	2434
2021 Q1	$45K	Buy	+1,739	New	+$44K	﹤0.01%	2101
2019 Q1	–	Sell	-2,282	Closed	-$15K	–	1953
2018 Q4	$15K	Sell	2,282 -4,144	-64%	-$32.9K	﹤0.01%	1852
2018 Q3	$66K	Sell	6,426 -6,700	-51%	-$57.7K	﹤0.01%	1674
2018 Q2	$88K	Buy	13,126 +7,700	+142%	+$59.1K	﹤0.01%	1869
2018 Q1	$47K	Buy	+5,426	New	+$102K	﹤0.01%	1995

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's PTGX Position: Q2 2025 in Review

Macquarie Group sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 283 shares — an estimated $13.7K sold.

Macquarie Group first reported a position in PTGX in Q1 2018 and held it in 11 quarters. The position peaked at $88K in Q2 2018. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

Macquarie Group reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
Macquarie Group sold 283 Protagonist Therapeutics shares in Q2 2025, an estimated $13.7K.
Macquarie Group first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 11 quarters.
Macquarie Group's Protagonist Therapeutics position peaked at $88K in Q2 2018.
272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Macquarie Group's 13F filing for Q2 2025, filed 14 Aug 2025.